BALAXI2025-04-012025-06-30BALAXI2025-06-30BALAXI2025-04-012025-06-30in-capmkt:OtherExpenses1MemberBALAXI2025-06-30

Statement1

BALAXI2025-04-012025-06-30

Statement1

BALAXI2025-06-30

StatementDynamic1I1

Statement1

iso4217:INRxbrli:pureiso4217:INRxbrli:shares

000000

BALAXI

NOTLISTED

INE618N01022

BALAXI PHARMACEUTICALS LIMITED

Main Board

Equity

2025-04-01

2026-03-31

2025-08-05

2025-07-29

INR

Lakhs

Quarterly

First quarter

Single segment

SPECIALIZED WHOLESALE

2025-08-05

11:10:00

2025-08-05

14:30:00

Not applicable

true

false

No default on Loans and Debt securities <BR>

2025-04-01

2025-06-30

Unaudited

Standalone

167082000

4622000

171704000

141759000

13135000

6310000

1128000

6789000

169121000

2583000

812000

-178000

634000

1949000

110415000

0.04

ADMINISTRATIVE EXPENSES

6789000

Preferential Issues

2022-10-11

47569225000000

2025-06-30

false

None

Ashish Maheshwari

Managing Director

Hyderabad

2025-08-05

The proceeds of the preferential issue shall be utilized to meet the capital expenditure requirements to support the construction of the Company’s first pharmaceutical formulation plant, being set up at Jadcherla, Hyderabad. Further, it may be utilized to meet working capital requirements and general corporate purposes and may also utilize to undertake any additional business activities under the main objects clause of the Memorandum of Association of the Company.

Not applicable

47569225000000

28631155549000